Carla Bastida
Overview
Explore the profile of Carla Bastida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Albanell-Fernandez M, Rodriguez-Reyes M, Bastida C, Soy D
Clin Pharmacokinet
. 2025 Jan;
64(1):1-25.
PMID: 39821208
Population pharmacokinetic (popPK) models are an essential tool when implementing therapeutic drug monitoring (TDM) and to overcome dosing challenges in neonates in clinical practice. Since vancomycin, gentamicin, and amikacin are...
2.
Escudero-Saiz V, Cuadrado-Payan E, Rodriguez-Garcia M, Casals G, Rodas L, Fontsere N, et al.
Toxins (Basel)
. 2024 Dec;
16(12).
PMID: 39728803
Pain is a frequent and disturbing symptom among hemodialysis patients. Protein-bound uremic toxins (PBUTs) are related to cardiovascular and overall mortality, and they are difficult to remove with current hemodialysis...
3.
Gras-Martin L, Plaza-Diaz A, Zarate-Tamames B, Vera-Artazcoz P, Torres O, Bastida C, et al.
Antibiotics (Basel)
. 2024 Sep;
13(9).
PMID: 39334976
(1) Background: Knowledge about the behavior of antibiotics in critically ill patients has been increasing in recent years. Some studies have concluded that a high percentage may be outside the...
4.
Roma J, Castro Rebollo P, Bastida C
Med Clin (Barc)
. 2024 Jul;
163(12):619-625.
PMID: 39004586
Drug administration is crucial to achieve effective therapeutic drug outcomes. In medical emergencies, it is particularly convenient to use drugs that could be administered as an alternative to traditional routes...
5.
Lizondo Lopez T, Font I Barcelo A, Garcia Gutierrez C, Blasco M, Grafia I, Bastida C, et al.
Eur J Hosp Pharm
. 2024 Jul;
PMID: 38964832
Thrombotic microangiopathy is a serious condition that can be precipitated by exposure to certain medications. Although rare, it is life threatening and requires a high index of clinical suspicion, appropriate...
6.
Escudero-Saiz V, Gonzalez A, Garcia-Herrera A, Larque A, Bomback A, Morantes L, et al.
Kidney Med
. 2024 May;
6(6):100823.
PMID: 38741947
C3 glomerulopathy is a rare disease caused by fluid phase dysregulation of the alternative complement pathway. Currently, treatment depends on clinical and histological severity and includes nephroprotection, unspecific immunosuppression, and...
7.
Hooijberg F, Layegh Z, Leeuw M, Boekel L, van den Berg S, Ruwaard J, et al.
Ther Drug Monit
. 2024 Jan;
46(3):410-414.
PMID: 38287880
Background: Tocilizumab in the treatment of rheumatoid arthritis (RA) is a potential candidate for concentration-guided tapering because the standard dose of tocilizumab results in a wide range of serum concentrations,...
8.
Albanell-Fernandez M, Bastida C, Marcos Fendian A, Mercadal J, Castro-Rebollo P, Soy-Muner D
Eur J Hosp Pharm
. 2023 May;
31(6):543-549.
PMID: 37137686
Objective: 24-hour urine creatinine clearance (ClCr 24 hours) remains the gold standard for estimating glomerular filtration rate (GFR) in critically ill patients; however, simpler methods are commonly used in clinical...
9.
Rodriguez-Espinosa D, Broseta J, Bastida C, Alvarez-Mora M, Nicolau C, Alvarez C, et al.
Nephron
. 2022 Sep;
147(3-4):152-157.
PMID: 36088902
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cause of end-stage kidney disease. Currently, tolvaptan is the only treatment that has proven to delay disease progression....
10.
Arranz N, Fernandez S, Bastida C
Med Clin (Barc)
. 2022 Sep;
159(12):e81-e82.
PMID: 36049973
No abstract available.